Copyright
©The Author(s) 2018.
World J Clin Cases. May 16, 2018; 6(5): 74-83
Published online May 16, 2018. doi: 10.12998/wjcc.v6.i5.74
Published online May 16, 2018. doi: 10.12998/wjcc.v6.i5.74
Table 1 Baseline characteristics of the study population
| Characteristics | Sorafenib + TACE (n = 38) | TACE (n = 29) | P value |
| Gender, Male/Female | 24 (63.2%)/14 (36.8%) | 18 (62.1%)/11 (37.9%) | > 0.05 |
| Age (mean ± SD, yr) | 52 ± 5 | 51 ± 6 | > 0.05 |
| ECOG PS 0/1/2/3/4 (%) | 38 (100%)/0 (0%)/0/(0%) 0/(0%) | 29 (100%)/0 (0%)/0/(0%) 0/(0%) | > 0.05 |
| Child-Pugh A/B | 25 (65.8%)/13 (34.2%) | 19 (65.5%)/10 (34.5%) | > 0.05 |
| Tumor diameter (cm) ≥ 6/< 6 | 14 (36.8%)/24 (63.2%) | 10 (34.5%)/19 (65.5%) | > 0.05 |
| Serum albumin (g/L) ≥ 35/< 35 | 20 (52.6%)/18 (47.4%) | 16 (55.2%)/13 (44.8%) | > 0.05 |
| Serum bilirubin (umol/L) ≥ 20/< 20 | 11 (28.9%)/27 (71.1%) | 8 (27.6%)/21 (72.4%) | > 0.05 |
| LDH (U/L) ≥ 245/< 245 | 23 (60.5%)/15 (39.5%) | 16 (55.2%)/13 (44.8%) | > 0.05 |
| AFP (ng/mL) ≥ 200/< 200 | 25 (65.8%)/13 (34.2%) | 19 (65.5%)/10 (34.5%) | > 0.05 |
| Number of TACE ≥ 2/< 2 | 19 (50.0%)/19 (50.0%) | 14 (48.3%)/15 (51.7%) | > 0.05 |
- Citation: Lei XF, Ke Y, Bao TH, Tang HR, Wu XS, Shi ZT, Lin J, Zhang ZX, Gu H, Wang L. Effect and safety of sorafenib in patients with intermediate hepatocellular carcinoma who received transarterial chemoembolization: A retrospective comparative study. World J Clin Cases 2018; 6(5): 74-83
- URL: https://www.wjgnet.com/2307-8960/full/v6/i5/74.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v6.i5.74